Related Experiment Video

Updated: Jan 8, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K

Effects of liraglutide on hemodynamic parameters in patients with heart failure

Jin Ying Zhang1, Xin Yun Wang1, Xiang Wang1

  • 1Department of Emergency, Binzhou Medical University Hospital, Binzhou, Shandong, China.

Oncotarget
|October 6, 2017
PubMed

Insights

Liraglutide, a glucagon-like peptide-1 analogue, significantly improved cardiac output and stroke volume in heart failure patients. This suggests potential benefits for left ventricular function in heart failure management.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 (GLP-1) analogues have shown promise in improving cardiac function, particularly after acute myocardial infarction.
  • Heart failure (HF) remains a significant clinical challenge with limited therapeutic options for improving hemodynamic parameters.
  • Investigating novel therapeutic targets like GLP-1 receptor agonists is crucial for advancing HF treatment.

Purpose of the Study:

  • To evaluate the efficacy of liraglutide, a GLP-1 analogue, in improving hemodynamic parameters in patients diagnosed with heart failure.
  • To assess the impact of liraglutide on cardiac output, stroke volume, and left ventricular contractile function.
  • To explore potential anti-inflammatory and anti-oxidative effects of liraglutide in the context of heart failure.

Main Methods:

  • A randomized controlled trial involving 52 heart failure patients, allocated 1:1 to receive either liraglutide or a placebo for 7 days.
  • Hemodynamic measurements were performed using advanced techniques, including transpulmonary thermodilution and arterial pulse contour analysis.
  • Changes in cardiac output, stroke volume, and left ventricular contractile index were primary and secondary endpoints.

Main Results:

  • Liraglutide treatment resulted in a statistically significant increase in cardiac output (+1.1 L/min) compared to placebo (P < 0.001).
  • Stroke volume was significantly elevated in the liraglutide group (+14.6 ml) versus the control group (P < 0.001).
  • A trend towards improved left ventricular contractile index was observed with liraglutide, alongside favorable changes in inflammation and oxidative stress markers.

Conclusions:

  • Short-term treatment with liraglutide demonstrates significant improvements in key hemodynamic parameters in patients with heart failure.
  • GLP-1 analogues, such as liraglutide, may represent a novel therapeutic strategy for enhancing left ventricular function in heart failure.
  • Larger, invasive trials are warranted to confirm these findings and establish the long-term clinical utility of liraglutide in heart failure management.

Keywords:
glucagon-like peptide-1heart failurehemodynamicleft ventricular functionpulse indicator continuous cardiac output

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
198
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
440
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
729
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
764